http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BR-9809330-A
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_94ff2d78578d95d1e8d3a2233c76188d |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61M15-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-14 |
filingDate | 1998-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_082a0d999a5b004686a6446e4472f313 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ea6c3d80798e1aa582c73fc823c2832 |
publicationDate | 2000-07-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | BR-9809330-A |
titleOfInvention | Halotherapy development process |
abstract | Invention Patent: <B> "HALOTHERAPY DEVELOPMENT PROCESS" <D>. Process for providing halotherapy to the upper part (22-26) of the lower respiratory tract (20), which includes the steps of operating a dispenser (30) and inhalation. The dispenser (30) contains a dry sodium chloride powder. The user operates the dispenser (30) to release a dosage of powder for inhalation when the dispenser (30) is directed to the user's mouth. The user then inhales the powder dosage through the mouth. Due to the fact that the powder has a particle size range that allows the powder to reach the upper part (22-26) of the lower respiratory tract (20) without being introduced into the user's lungs, the dry powder dosage presents a concentration at the top (22-26) enough to provide effective halotherapy. The preferred particle size is about 5 microns to about 20 microns. The preferred dosage is about 3 milligrams of powder. |
priorityDate | 1997-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Predicate | Subject |
---|---|
isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234 |
Total number of triples: 14.